ClinicalTrials.gg
CompletedNCT04143594CALIBRATEUpdated Oct 2, 2024Results posted

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV

A Phase 2 interventional study of Oral Lenacapavir and F/TAF in HIV-1-infection, sponsored by Gilead Sciences. Completed at 53 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-02.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
183
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to evaluate the efficacy of lenacapavir (formerly GS-6207) containing regimens in people living with human immunodeficiency virus (HIV) (PLWH).

02

Conditions studied

  • HIV-1-infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Antiretroviral (ARV) naive with no use of any ARV within one month of screening. Use of pre-exposure prophylaxis (PrEP) (any duration), post-exposure prophylaxis (PEP) (any duration), or -1 treatment (\< 10 days therapy total) > 1 month prior to screening is permitted
  • HIV-1 ribonucleic acid (RNA) ≥ 200 copies/mL at screening
  • Cluster Determinant 4+ (CD4+) cell count ≥ 200 cells/microliter at screening

Key Exclusion Criteria:

  • Current Virus (HBV) or virus (HCV) infection

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
183 participants (actual)

Study arms

  • Experimental
    Lenacapavir, F/TAF, and TAF

    Induction phase: Participants will receive lenacapavir (LEN) 600 mg (2 X 300 mg, tablet) orally on Days 1 and 2, followed by LEN 300 mg tablet orally on Day 8 plus emtricitabine/ tenofovir alafenamide (F/TAF) (200/25 mg) fixed-dose combination (FDC) tablets once daily orally from Day 1 to Week 28 plus LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via subcutaneous (SC) injection on Day 15. Maintenance phase: Participants will receive LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Week 28 and every 6 months (26 weeks) thereafter plus TAF 25 mg tablets once daily orally at Week 28 and will continue up to Week 80. Participants willing to continue the study beyond Week 80 will continue to receive SC LEN 927 mg injection every 6 months (26 weeks) and oral daily TAF 25 mg tablets from Week 80 onwards.

    Drug: Oral Lenacapavir · Drug: F/TAF · Drug: Subcutaneous Lenacapavir · Drug: TAF

  • Experimental
    Lenacapavir, F/TAF, and BIC

    Induction phase: Participants will receive LEN 600 mg (2 X 300 mg, tablet) orally on Days 1 and 2, followed by LEN 300 mg tablet orally on Day 8 plus F/TAF (200/25 mg) FDC tablets once daily orally from Day 1 to Week 28 plus LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Day 15. Maintenance phase: Participants will receive LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Week 28 and every 6 months (26 weeks) thereafter plus bictegravir (BIC) 75 mg tablets once daily orally at Week 28 and will continue up to Week 80. Participants willing to continue the study beyond Week 80 will continue to receive SC LEN 927 mg injection every 6 months (26 weeks) and oral daily BIC 75 mg tablets from Week 80 onwards.

    Drug: Oral Lenacapavir · Drug: F/TAF · Drug: Subcutaneous Lenacapavir · Drug: BIC

  • Experimental
    Lenacapavir and F/TAF

    Induction phase: Participants will receive LEN 600 mg (2 X 300 mg, tablet) orally on Days 1 and 2, followed by LEN 300 mg tablet orally on Day 8 plus F/TAF (200/25 mg) FDC tablets once daily orally from Day 1 to Week 28 plus LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Day 15. Maintenance phase: Participants will receive LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Week 28 and every 6 months (26 weeks) thereafter plus bictegravir (BIC) 75 mg tablets once daily orally at Week 28 and will continue up to Week 80. Participants willing to continue the study beyond Week 80 will continue to receive SC LEN 927 mg injection every 6 months (26 weeks) and oral daily BIC 75 mg tablets from Week 80 onwards.

    Drug: Oral Lenacapavir · Drug: F/TAF

  • Active comparator
    B/F/TAF

    Participants will receive bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) (50/200/25 mg) FDC tablets once daily orally from Day 1 and throughout their participation in the study up to Week 80

    Drug: B/F/TAF

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 54 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 54 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 54 window was between Day 323 and 413 (inclusive). Percentages were rounded off.

    Time frame: Week 54

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 28 as Determined by the US FDA-defined Snapshot Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 28 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 28 window was between Days 176 and 231 (inclusive). Percentages were rounded off.

    Time frame: Week 28

  2. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 38 as Determined by the US FDA-defined Snapshot Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 38 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 38 window was between Days 232 and 322 (inclusive). Percentages were rounded off.

    Time frame: Week 38

  3. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 80 as Determined by the US FDA-defined Snapshot Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 80 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. The Week 80 window was between Days 505 and 595 (inclusive). Percentages were rounded off.

    Time frame: Week 80

  4. Change From Baseline in Log10 HIV-1 RNA at Week 28

    Time frame: Baseline, Week 28

  5. Change From Baseline in Log10 HIV-1 RNA at Week 38

    Time frame: Baseline, Week 38

  6. Change From Baseline in Log10 HIV-1 RNA at Week 54

    Time frame: Baseline, Week 54

  7. Change From Baseline in Log10 HIV-1 RNA at Week 80

    Time frame: Baseline, Week 80

  8. Change From Baseline in Clusters of Differentiation 4+ (CD4+) Cell Count at Week 28

    Time frame: Baseline, Week 28

  9. Change From Baseline in CD4+ Cell Count at Week 38

    Time frame: Baseline, Week 38

  10. Change From Baseline in CD4+ Cell Count at Week 54

    Time frame: Baseline, Week 54

  11. Change From Baseline in CD4+ Cell Count at Week 80

    Time frame: Baseline, Week 80

  12. Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)

    TEAEs were defined as 1 or both of any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. Percentages were rounded off.

    Time frame: Up to 174.9 weeks

  13. Percentage of Participants Who Experienced Maximum Postbaseline Laboratory Abnormalities

    Treatment-emergent laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any postbaseline visit, up to last exposure date for participants who permanently discontinued study drug. Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening. Percentages were rounded off.

    Time frame: Up to 174.9 weeks

  14. Pharmacokinetics (PK) of LEN: Plasma LEN Pre-dose Concentrations for SC LEN

    Time frame: Day 2, 8, Day 1 SC (Day 15), Week 28 and Week 54

  15. PK of LEN : Plasma LEN Single Anytime Concentrations for the Oral LEN + DVY

    Time frame: Day 2, 8, 15 , Week 28 and Week 54

  16. PK of TAF (Tenofovir Alafenamide) and TFV (Tenofovir): Area Under the Concentration Versus Time Curve (AUClast) on Day 1

    AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2) and at least 15 participants in the treatment group receiving oral LEN (Treatment Group 3). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 and 2 on Day 1.

    Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose on Day 1

  17. PK of TAF and TFV (Tenofovir): Maximum Observed Concentration of Drug (Cmax) on Day 1

    Cmax is defined as the maximum observed concentration of drug. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 and 2 on Day 1.

    Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose on Day 1

  18. PK of TAF and TFV: Time (Observed Time Point) of Cmax (Tmax) on Day 1

    Tmax is defined as the time (observed time point) of Cmax. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 and 2 on Day 1.

    Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose on Day 1

  19. PK of TFV: Last Observed Quantifiable Concentration of the Drug (Clast) on Day 1

    Clast is defined as the last observable concentration of drug. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK sub study analysis was conducted for Group 1 and 2 on Day 1.

    Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose on Day 1

  20. PK of TAF and TFV: AUClast at Weeks 16, 22, or 28

    AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. A PK substudy was conducted in at least 15 participants in the treatment group receiving oral LEN (Treatment Group 3). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. For each participant, PK samples were taken at only one of the three possible visits: Weeks 16, 22, or 28. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.

    Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose

  21. PK of TAF and TFV: Cmax at Weeks 16, 22, or 28

    Cmax is defined as the maximum observed concentration of drug. A PK substudy was conducted in at least 15 participants in the treatment group receiving oral LEN (Treatment Group 3). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. For each participant, PK samples were taken at only one of the three possible visits: Weeks 16, 22, or 28. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.

    Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose

  22. PK of TAF and TFV: Tmax at Weeks 16, 22, or 28

    Tmax is defined as the time (observed time point) of Cmax. A PK substudy was conducted in at least 15 participants in the treatment group receiving oral LEN (Treatment Group 3). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. For each participant, PK samples were taken at only one of the three possible visits: Weeks 16, 22, or 28. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.

    Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose

  23. PK of TFV: Clast at Weeks 16, 22, or 28

    Clast is defined as the last observable concentration of drug. A PK substudy was conducted in at least 15 participants in the treatment group receiving oral LEN (Treatment Group 3). Key PK parameters of TFV was summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. For each participant, PK samples were taken at only one of the three possible visits: Weeks 16, 22, or 28. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.

    Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose

  24. PK of TAF: AUClast at Week 38

    AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TAF was summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 at Week 38.

    Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose

  25. PK of TAF: Cmax at Week 38

    Cmax is defined as the maximum observed concentration of drug. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TAF was summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 at Week 38.

    Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose

  26. PK of TAF: Tmax at Week 38

    Tmax is defined as the time (observed time point) of Cmax. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TAF was summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 at Week 38.

    Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose

  27. PK of Tenofovir Diphosphate (TFV-DP): AUClast at Weeks 4, 10, 16, or 22

    AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. A peripheral blood mononuclear cell (PBMC) substudy was conducted in a total of approximately 15 participants in Treatment Groups 1 and 2. For each participant, PK samples were taken at only one of the four possible visits: Weeks 4, 10, 16, or 22. A 12-hour postdose sample was collected, if possible. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.

    Time frame: 0 hours (Predose) and at 1, 2, and 6 hours postdose

  28. PK of TFV-DP: Cmax at Weeks 4, 10, 16, or 22

    Cmax is defined as the maximum observed concentration of drug. A PBMC substudy was conducted in a total of approximately 15 participants in Treatment Groups 1 and 2. For each participant, PK samples were taken at only one of the four possible visits: Weeks 4, 10, 16, or 22. A 12-hour postdose sample was collected, if possible. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.

    Time frame: 0 hours (Predose) and at 1, 2, and 6 hours postdose

  29. PK of TFV-DP: Tmax at Weeks 4, 10, 16, or 22

    Tmax is defined as the time (observed time point) of Cmax. A PBMC substudy was conducted in a total of approximately 15 participants in Treatment Groups 1 and 2. For each participant, PK samples were taken at only one of the four possible visits: Weeks 4, 10, 16, or 22. A 12-hour postdose sample was collected, if possible. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.

    Time frame: 0 hours (Predose) and at 1, 2, and 6 hours postdose

  30. PK of Bictegravir (BIC): AUClast at Week 38

    AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). At Week 38, samples were analyzed for BIC only in Treatment Group 2.

    Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose

  31. PK of BIC: Cmax at Week 38

    Cmax is defined as the maximum observed concentration of drug. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). At Week 38, samples were analyzed for BIC only in Treatment Group 2.

    Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose

  32. PK of BIC: Tmax at Week 38

    Tmax is defined as the time (observed time point) of Cmax. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). At Week 38, samples were analyzed for BIC only in Treatment Group 2.

    Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose

  33. PK of BIC: Clast at Week 38

    Clast is defined as the last observable concentration of drug. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). At Week 38, samples were analyzed for BIC only in Treatment Group 2.

    Time frame: 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose

07

Results

Posted Dec 19, 2022

Participant flow

Participants were enrolled at study sites in Dominican Republic, Puerto Rico, and the United States.

Participant flow — Overall Study
MilestoneGroup 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)Group 3: Oral LEN + F/TAFGroup 4: B/F/TAF
Started52535226
Completed41353624
Not completed1118162
Withdrew: Withdrew consent31031
Withdrew: Lost to follow-up35110
Withdrew: Investigator's discretion2200
Withdrew: Randomized but never treated0001
Withdrew: Death1010
Withdrew: Adverse event1000
Withdrew: Pregnancy0010
Withdrew: Lack of efficacy1100

Outcome measures

PrimaryPercentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 54 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 54 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 54 window was between Day 323 and 413 (inclusive). Percentages were rounded off.

Time frame:
Week 54
Reported as:
Number · percentage of participants
Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 54 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm
percentage of participantsGroup 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)Group 3: Oral LEN + F/TAFGroup 4: B/F/TAF
Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 54 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm90.484.984.692.0
Statistical analysis
  • Group 1: SC LEN+(F/TAF→ TAF) vs Group 4: B/F/TAF · Cochran-Mantel-Haenszel · p = 0.7178 (P-value was from the Cochran-Mantel-Haenszel (CMH) tests stratified by baseline HIV-1 RNA stratum (≤ 100,000 vs \> 100,000 copies/mL).) · Difference in percentage: -2.6 · 95% CI -18.4 to 13.2The difference in percentage of participants between LEN-containing and the B/F/TAF groups, and its 95% confidence interval (CI) were calculated based on the MH proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs \> 100,000 copies/mL).
  • Group 2: SC LEN + (F/TAF → BIC) vs Group 4: B/F/TAF · Cochran-Mantel-Haenszel · p = 0.3900 (P-value was from the CMH tests stratified by baseline HIV-1 RNA stratum (\<= 100,000 vs. \> 100,000 copies/mL).) · Difference in percentage: -7.1 · 95% CI -23.4 to 9.3The difference in percentage of participants between LEN-containing treatment groups and the B/F/TAF group, and its 95% CI were calculated based on the MH proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs \> 100,000 copies/mL).
  • Group 3: Oral LEN + F/TAF vs Group 4: B/F/TAF · Cochran-Mantel-Haenszel · p = 0.3797 (P-value was from the CMH tests stratified by baseline HIV-1 RNA stratum (\<= 100,000 vs. \> 100,000 copies/mL).) · Difference in percentage: -7.2 · 95% CI -23.5 to 9.1The difference in percentage of participants between LEN-containing treatment groups and the B/F/TAF group, and its 95% CI were calculated based on the MH proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs \> 100,000 copies/mL).
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 28 as Determined by the US FDA-defined Snapshot Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 28 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 28 window was between Days 176 and 231 (inclusive). Percentages were rounded off.

Time frame:
Week 28
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 28 as Determined by the US FDA-defined Snapshot Algorithm
percentage of participantsGroup 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)Group 3: Oral LEN + F/TAFGroup 4: B/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 28 as Determined by the US FDA-defined Snapshot Algorithm94.292.594.2100.0
Statistical analysis
  • Group 1: SC LEN+(F/TAF→ TAF) vs Group 4: B/F/TAF · Cochran-Mantel-Haenszel · p = 0.2398 (P-value was from the CMH tests stratified by baseline HIV-1 RNA stratum (\<= 100,000 vs. \> 100,000 copies/mL).) · Difference in percentage: -5.5 · 95% CI -15.9 to 4.8The difference in percentage of participants between LEN-containing treatment groups and the B/F/TAF group, and its 95% CI were calculated based on the MH proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs \> 100,000 copies/mL).
  • Group 2: SC LEN + (F/TAF → BIC) vs Group 4: B/F/TAF · Cochran-Mantel-Haenszel · p = 0.1639 (P-value was from the CMH tests stratified by baseline HIV-1 RNA stratum (\<= 100,000 vs. \> 100,000 copies/mL).) · Difference in percentage: -7.4 · 95% CI -18.3 to 3.4The difference in percentage of participants between LEN-containing treatment groups and the B/F/TAF group, and its 95% CI were calculated based on the MH proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs \> 100,000 copies/mL).
  • Group 3: Oral LEN + F/TAF vs Group 4: B/F/TAF · Cochran-Mantel-Haenszel · p = 0.2307 (P-value was from the CMH tests stratified by baseline HIV-1 RNA stratum (\<= 100,000 vs. \> 100,000 copies/mL).) · Difference in percentage: -5.7 · 95% CI -16.3 to 4.9The difference in percentage of participants between LEN-containing treatment groups and the B/F/TAF group, and its 95% CI were calculated based on the MH proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs \> 100,000 copies/mL).
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 38 as Determined by the US FDA-defined Snapshot Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 38 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 38 window was between Days 232 and 322 (inclusive). Percentages were rounded off.

Time frame:
Week 38
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 38 as Determined by the US FDA-defined Snapshot Algorithm
percentage of participantsGroup 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)Group 3: Oral LEN + F/TAFGroup 4: B/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 38 as Determined by the US FDA-defined Snapshot Algorithm90.488.788.596.0
Statistical analysis
  • Group 1: SC LEN+(F/TAF→ TAF) vs Group 4: B/F/TAF · Cochran-Mantel-Haenszel · p = 0.3142 (P-value was from the CMH tests stratified by baseline HIV-1 RNA stratum (\<= 100,000 vs. \> 100,000 copies/mL).) · Difference in percentage: -6.7 · 95% CI -20.7 to 7.3The difference in percentage of participants between LEN-containing treatment groups and the B/F/TAF group, and its 95% CI were calculated based on the MH proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs \> 100,000 copies/mL).
  • Group 2: SC LEN + (F/TAF → BIC) vs Group 4: B/F/TAF · Cochran-Mantel-Haenszel · p = 0.3009 (P-value was from the CMH tests stratified by baseline HIV-1 RNA stratum (\<= 100,000 vs. \> 100,000 copies/mL).) · Difference in percentage: -7.2 · 95% CI -21.3 to 6.8The difference in percentage of participants between LEN-containing treatment groups and the B/F/TAF group, and its 95% CI were calculated based on the MH proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs \> 100,000 copies/mL).
  • Group 3: Oral LEN + F/TAF vs Group 4: B/F/TAF · Cochran-Mantel-Haenszel · p = 0.2859 (P-value was from the CMH tests stratified by baseline HIV-1 RNA stratum (\<= 100,000 vs. \> 100,000 copies/mL).) · Difference in percentage: -7.6 · 95% CI -21.8 to 6.7The difference in percentage of participants between LEN-containing treatment groups and the B/F/TAF group, and its 95% CI were calculated based on the MH proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs \> 100,000 copies/mL).
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 80 as Determined by the US FDA-defined Snapshot Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 80 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. The Week 80 window was between Days 505 and 595 (inclusive). Percentages were rounded off.

Time frame:
Week 80
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 80 as Determined by the US FDA-defined Snapshot Algorithm
percentage of participantsGroup 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)Group 3: Oral LEN + F/TAFGroup 4: B/F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 80 as Determined by the US FDA-defined Snapshot Algorithm86.575.586.592
Statistical analysis
  • Group 1: SC LEN+(F/TAF→ TAF) vs Group 4: B/F/TAF · Cochran-Mantel-Haenszel · p = 0.3686 (P-value was from the CMH tests stratified by baseline HIV-1 RNA stratum (\<= 100,000 vs. \> 100,000 copies/mL).) · Difference in percentage: -7.1 · 95% CI -23.2 to 9.0The difference in percentage of participants between LEN-containing treatment groups and the B/F/TAF group, and its 95% CI were calculated based on the MH proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs \> 100,000 copies/mL).
  • Group 2: SC LEN + (F/TAF → BIC) vs Group 4: B/F/TAF · Cochran-Mantel-Haenszel · p = 0.0887 (P-value was from the CMH tests stratified by baseline HIV-1 RNA stratum (\<= 100,000 vs. \> 100,000 copies/mL).) · Difference in percentage: -16.5 · 95% CI -34.0 to 1.0The difference in percentage of participants between LEN-containing treatment groups and the B/F/TAF group, and its 95% CI were calculated based on the MH proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs \> 100,000 copies/mL).
  • Group 3: Oral LEN + F/TAF vs Group 4: B/F/TAF · Cochran-Mantel-Haenszel · p = 0.4949 (P-value was from the CMH tests stratified by baseline HIV-1 RNA stratum (\<= 100,000 vs. \> 100,000 copies/mL).) · Difference in percentage: -5.4 · 95% CI -21.5 to 10.7The difference in percentage of participants between LEN-containing treatment groups and the B/F/TAF group, and its 95% CI were calculated based on the MH proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs \> 100,000 copies/mL).
SecondaryChange From Baseline in Log10 HIV-1 RNA at Week 28
Time frame:
Baseline, Week 28
Reported as:
Mean · log10 copies/mL
Change From Baseline in Log10 HIV-1 RNA at Week 28
log10 copies/mLGroup 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)Group 3: Oral LEN + F/TAFGroup 4: B/F/TAF
Change From Baseline in Log10 HIV-1 RNA at Week 28-2.92 ± 0.649-3.04 ± 0.638-3.01 ± 0.716-3.07 ± 0.774
Statistical analysis
  • Group 1: SC LEN+(F/TAF→ TAF) vs Group 4: B/F/TAF · ANOVA · p = 0.5755 (P-value was from analysis of variance (ANOVA) model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).) · Difference in lsm: 0.08 · 95% CI -0.20 to 0.37Difference in least squares means (Diff in LSM), and its 95% CI were from ANOVA model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).
  • Group 2: SC LEN + (F/TAF → BIC) vs Group 4: B/F/TAF · ANOVA · p = 0.8697 (P-value was from (ANOVA) model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).) · Difference in lsm: 0.02 · 95% CI -0.25 to 0.29Difference in LSM, and its 95% CI were from ANOVA model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).
  • Group 3: Oral LEN + F/TAF vs Group 4: B/F/TAF · ANOVA · p = 0.7052 (P-value was from (ANOVA) model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).) · Difference in lsm: 0.06 · 95% CI -0.23 to 0.35Difference in LSM, and its 95% CI were from ANOVA model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).
SecondaryChange From Baseline in Log10 HIV-1 RNA at Week 38
Time frame:
Baseline, Week 38
Reported as:
Mean · log10 copies/mL
Change From Baseline in Log10 HIV-1 RNA at Week 38
log10 copies/mLGroup 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)Group 3: Oral LEN + F/TAFGroup 4: B/F/TAF
Change From Baseline in Log10 HIV-1 RNA at Week 38-2.96 ± 0.639-3.06 ± 0.641-3.02 ± 0.771-3.04 ± 0.760
Statistical analysis
  • Group 1: SC LEN+(F/TAF→ TAF) vs Group 4: B/F/TAF · ANOVA · p = 0.8942 (P-value was from (ANOVA) model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).) · Difference in lsm: 0.02 · 95% CI -0.26 to 0.30Difference in LSM, and its 95% CI were from ANOVA model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).
  • Group 2: SC LEN + (F/TAF → BIC) vs Group 4: B/F/TAF · ANOVA · p = 0.9058 (P-value was from (ANOVA) model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).) · Difference in lsm: -0.02 · 95% CI -0.28 to 0.25Difference in LSM, and its 95% CI were from ANOVA model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).
  • Group 3: Oral LEN + F/TAF vs Group 4: B/F/TAF · ANOVA · p = 0.8129 (P-value was from (ANOVA) model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).) · Difference in lsm: 0.04 · 95% CI -0.27 to 0.35Difference in LSM, and its 95% CI were from ANOVA model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).
SecondaryChange From Baseline in Log10 HIV-1 RNA at Week 54
Time frame:
Baseline, Week 54
Reported as:
Mean · log10 copies/mL
Change From Baseline in Log10 HIV-1 RNA at Week 54
log10 copies/mLGroup 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)Group 3: Oral LEN + F/TAFGroup 4: B/F/TAF
Change From Baseline in Log10 HIV-1 RNA at Week 54-2.95 ± 0.636-3.12 ± 0.589-2.85 ± 0.840-3.08 ± 0.787
Statistical analysis
  • Group 1: SC LEN+(F/TAF→ TAF) vs Group 4: B/F/TAF · ANOVA · p = 0.7864 (P-value was from (ANOVA) model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).) · Difference in lsm: 0.04 · 95% CI -0.25 to 0.33Difference in LSM, and its 95% CI were from ANOVA model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).
  • Group 2: SC LEN + (F/TAF → BIC) vs Group 4: B/F/TAF · ANOVA · p = 0.7013 (P-value was from (ANOVA) model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).) · Difference in lsm: -0.05 · 95% CI -0.31 to 0.21Difference in LSM, and its 95% CI were from ANOVA model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).
  • Group 3: Oral LEN + F/TAF vs Group 4: B/F/TAF · ANOVA · p = 0.2753 (P-value was from (ANOVA) model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).) · Difference in lsm: 0.22 · 95% CI -0.18 to 0.62Difference in LSM, and its 95% CI were from ANOVA model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).
SecondaryChange From Baseline in Log10 HIV-1 RNA at Week 80
Time frame:
Baseline, Week 80
Reported as:
Mean · log10 Copies/mL
Change From Baseline in Log10 HIV-1 RNA at Week 80
log10 Copies/mLGroup 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)Group 3: Oral LEN + F/TAFGroup 4: B/F/TAF
Change From Baseline in Log10 HIV-1 RNA at Week 80-2.96 ± 0.539-3.08 ± 0.592-2.96 ± 0.747-3.09 ± 0.755
Statistical analysis
  • Group 1: SC LEN+(F/TAF→ TAF) vs Group 4: B/F/TAF · ANOVA · p = 0.5640 (P-value was from (ANOVA) model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).) · Difference in lsm: 0.08 · 95% CI -0.19 to 0.34Difference in LSM, and its 95% CI were from ANOVA model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).
  • Group 2: SC LEN + (F/TAF → BIC) vs Group 4: B/F/TAF · ANOVA · p = 0.9555 (P-value was from (ANOVA) model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).) · Difference in lsm: -0.01 · 95% CI -0.28 to 0.26Difference in LSM, and its 95% CI were from ANOVA model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).
  • Group 3: Oral LEN + F/TAF vs Group 4: B/F/TAF · ANOVA · p = 0.4025 (P-value was from (ANOVA) model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).) · Difference in lsm: 0.14 · 95% CI -0.19 to 0.46Difference in LSM, and its 95% CI were from ANOVA model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).
SecondaryChange From Baseline in Clusters of Differentiation 4+ (CD4+) Cell Count at Week 28
Time frame:
Baseline, Week 28
Reported as:
Mean · cells/µL
Change From Baseline in Clusters of Differentiation 4+ (CD4+) Cell Count at Week 28
cells/µLGroup 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)Group 3: Oral LEN + F/TAFGroup 4: B/F/TAF
Change From Baseline in Clusters of Differentiation 4+ (CD4+) Cell Count at Week 28172 ± 178.2158 ± 164.1206 ± 154.6163 ± 157.7
Statistical analysis
  • Group 1: SC LEN+(F/TAF→ TAF) vs Group 4: B/F/TAF · ANOVA · p = 0.7751 (P-value was from (ANOVA) model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).) · Difference in lsm: 12 · 95% CI -73 to 97Difference in LSM, and its 95% CI were from ANOVA model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).
  • Group 2: SC LEN + (F/TAF → BIC) vs Group 4: B/F/TAF · ANOVA · p = 0.9549 (P-value was from (ANOVA) model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).) · Difference in lsm: -2 · 95% CI -79 to 75Difference in LSM, and its 95% CI were from ANOVA model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).
  • Group 3: Oral LEN + F/TAF vs Group 4: B/F/TAF · ANOVA · p = 0.2603 (P-value was from (ANOVA) model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).) · Difference in lsm: 44 · 95% CI -33 to 120Difference in LSM, and its 95% CI were from ANOVA model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).
SecondaryChange From Baseline in CD4+ Cell Count at Week 38
Time frame:
Baseline, Week 38
Reported as:
Mean · cells/µL
Change From Baseline in CD4+ Cell Count at Week 38
cells/µLGroup 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)Group 3: Oral LEN + F/TAFGroup 4: B/F/TAF
Change From Baseline in CD4+ Cell Count at Week 38195 ± 164.6220 ± 187.5211 ± 166.2232 ± 209.3
Statistical analysis
  • Group 1: SC LEN+(F/TAF→ TAF) vs Group 4: B/F/TAF · ANOVA · p = 0.4827 (P-value was from (ANOVA) model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).) · Difference in lsm: -31 · 95% CI -119 to 57Difference in LSM, and its 95% CI were from ANOVA model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).
  • Group 2: SC LEN + (F/TAF → BIC) vs Group 4: B/F/TAF · ANOVA · p = 0.7963 (P-value was from (ANOVA) model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).) · Difference in lsm: -12 · 95% CI -106 to 81Difference in LSM, and its 95% CI were from ANOVA model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).
  • Group 3: Oral LEN + F/TAF vs Group 4: B/F/TAF · ANOVA · p = 0.6169 (P-value was from (ANOVA) model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).) · Difference in lsm: -22 · 95% CI -111 to 67Difference in LSM, and its 95% CI were from ANOVA model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).
SecondaryChange From Baseline in CD4+ Cell Count at Week 54
Time frame:
Baseline, Week 54
Reported as:
Mean · cells/µL
Change From Baseline in CD4+ Cell Count at Week 54
cells/µLGroup 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)Group 3: Oral LEN + F/TAFGroup 4: B/F/TAF
Change From Baseline in CD4+ Cell Count at Week 54204 ± 189.1213 ± 187.2220 ± 175.5193 ± 191.1
Statistical analysis
  • Group 1: SC LEN+(F/TAF→ TAF) vs Group 4: B/F/TAF · ANOVA · p = 0.6614 (P-value was from (ANOVA) model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).) · Difference in lsm: 21 · 95% CI -73 to 115Difference in LSM, and its 95% CI were from ANOVA model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).
  • Group 2: SC LEN + (F/TAF → BIC) vs Group 4: B/F/TAF · ANOVA · p = 0.6791 (P-value was from (ANOVA) model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).) · Difference in lsm: 20 · 95% CI -75 to 115Difference in LSM, and its 95% CI were from ANOVA model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).
  • Group 3: Oral LEN + F/TAF vs Group 4: B/F/TAF · ANOVA · p = 0.5563 (P-value was from (ANOVA) model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).) · Difference in lsm: 27 · 95% CI -65 to 120Difference in LSM, and its 95% CI were from ANOVA model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).
SecondaryChange From Baseline in CD4+ Cell Count at Week 80
Time frame:
Baseline, Week 80
Reported as:
Mean · cells/μL
Change From Baseline in CD4+ Cell Count at Week 80
cells/μLGroup 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)Group 3: Oral LEN + F/TAFGroup 4: B/F/TAF
Change From Baseline in CD4+ Cell Count at Week 80275 ± 211.8262 ± 184.4245 ± 237.4248 ± 218.7
Statistical analysis
  • Group 1: SC LEN+(F/TAF→ TAF) vs Group 4: B/F/TAF · ANOVA · p = 0.5492 (P-value was from (ANOVA) model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).) · Difference in lsm: 32 · 95% CI -75 to 140Difference in LSM, and its 95% CI were from ANOVA model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).
  • Group 2: SC LEN + (F/TAF → BIC) · Difference in LSM · p = 0.7220 (P-value was from (ANOVA) model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).) · Difference in lsm: 17 · 95% CI -80 to 115Difference in LSM, and its 95% CI were from ANOVA model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).
  • Group 3: Oral LEN + F/TAF vs Group 4: B/F/TAF · ANOVA · p = 0.9486 (P-value was from (ANOVA) model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).) · Difference in lsm: -4 · 95% CI -118 to 110Difference in LSM, and its 95% CI were from ANOVA model adjusting for the baseline HIV-1 RNA level (\<= 100,000 copies/mL or \> 100,000 copies/mL).
SecondaryPercentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)

TEAEs were defined as 1 or both of any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. Percentages were rounded off.

Time frame:
Up to 174.9 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
percentage of participantsGroup 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)Group 3: Oral LEN + F/TAFGroup 4: B/F/TAF
Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)98.188.790.484.0
SecondaryPercentage of Participants Who Experienced Maximum Postbaseline Laboratory Abnormalities

Treatment-emergent laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any postbaseline visit, up to last exposure date for participants who permanently discontinued study drug. Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening. Percentages were rounded off.

Time frame:
Up to 174.9 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Maximum Postbaseline Laboratory Abnormalities
percentage of participantsGroup 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)Group 3: Oral LEN + F/TAFGroup 4: B/F/TAF
Grade 19.63.89.60
Grade 255.856.642.376.0
Grade 317.328.330.824.0
Grade 413.59.413.50
SecondaryPharmacokinetics (PK) of LEN: Plasma LEN Pre-dose Concentrations for SC LEN
Time frame:
Day 2, 8, Day 1 SC (Day 15), Week 28 and Week 54
Reported as:
Mean · ng/mL
Pharmacokinetics (PK) of LEN: Plasma LEN Pre-dose Concentrations for SC LEN
ng/mLGroup 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)
Day 228.3 ± 27.1526.1 ± 20.46
Day 834.5 ± 20.9632.1 ± 14.71
Day 1 SC (Day 15)30.9 ± 16.7631.2 ± 14.66
Week 2822.0 ± 11.7023.0 ± 14.81
Week 5426.9 ± 14.1926.4 ± 12.10
SecondaryPK of LEN : Plasma LEN Single Anytime Concentrations for the Oral LEN + DVY
Time frame:
Day 2, 8, 15 , Week 28 and Week 54
Reported as:
Mean · ng/mL
PK of LEN : Plasma LEN Single Anytime Concentrations for the Oral LEN + DVY
ng/mLGroup 3: Oral LEN + F/TAF
Day 229.8 ± 42.70
Day 878.7 ± 55.90
Day 1597.2 ± 67.25
Week 2896.6 ± 76.40
Week 5498.4 ± 85.25
SecondaryPK of TAF (Tenofovir Alafenamide) and TFV (Tenofovir): Area Under the Concentration Versus Time Curve (AUClast) on Day 1

AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2) and at least 15 participants in the treatment group receiving oral LEN (Treatment Group 3). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 and 2 on Day 1.

Time frame:
0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose on Day 1
Reported as:
Mean · hours*nanogram/mL (h*ng/mL)
PK of TAF (Tenofovir Alafenamide) and TFV (Tenofovir): Area Under the Concentration Versus Time Curve (AUClast) on Day 1
hours*nanogram/mL (h*ng/mL)Group 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)
TAF298.0 ± 88.0260.0 ± 63.5
TFV27.1 ± 27.940.5 ± 59.7
SecondaryPK of TAF and TFV (Tenofovir): Maximum Observed Concentration of Drug (Cmax) on Day 1

Cmax is defined as the maximum observed concentration of drug. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 and 2 on Day 1.

Time frame:
0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose on Day 1
Reported as:
Mean · ng/mL
PK of TAF and TFV (Tenofovir): Maximum Observed Concentration of Drug (Cmax) on Day 1
ng/mLGroup 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)
TAF278.8 ± 87.7318.4 ± 57.7
TFV5.4 ± 26.513.8 ± 160.2
SecondaryPK of TAF and TFV: Time (Observed Time Point) of Cmax (Tmax) on Day 1

Tmax is defined as the time (observed time point) of Cmax. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 and 2 on Day 1.

Time frame:
0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose on Day 1
Reported as:
Median · hours
PK of TAF and TFV: Time (Observed Time Point) of Cmax (Tmax) on Day 1
hoursGroup 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)
TAF0.50 (0.50 to 1.00)0.50 (0.50 to 0.50)
TFV1.50 (1.00 to 2.02)1.00 (0.50 to 1.17)
SecondaryPK of TFV: Last Observed Quantifiable Concentration of the Drug (Clast) on Day 1

Clast is defined as the last observable concentration of drug. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK sub study analysis was conducted for Group 1 and 2 on Day 1.

Time frame:
0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose on Day 1
Reported as:
Mean · ng/mL
PK of TFV: Last Observed Quantifiable Concentration of the Drug (Clast) on Day 1
ng/mLGroup 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)
PK of TFV: Last Observed Quantifiable Concentration of the Drug (Clast) on Day 12.7 ± 23.13.9 ± 38.0
SecondaryPK of TAF and TFV: AUClast at Weeks 16, 22, or 28

AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. A PK substudy was conducted in at least 15 participants in the treatment group receiving oral LEN (Treatment Group 3). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. For each participant, PK samples were taken at only one of the three possible visits: Weeks 16, 22, or 28. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.

Time frame:
0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose
Reported as:
Mean · h*ng/mL
PK of TAF and TFV: AUClast at Weeks 16, 22, or 28
h*ng/mLGroup 3: Oral LEN + F/TAF
TAF231.2 ± 60.0
TFV173.1 ± 52.5
SecondaryPK of TAF and TFV: Cmax at Weeks 16, 22, or 28

Cmax is defined as the maximum observed concentration of drug. A PK substudy was conducted in at least 15 participants in the treatment group receiving oral LEN (Treatment Group 3). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. For each participant, PK samples were taken at only one of the three possible visits: Weeks 16, 22, or 28. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.

Time frame:
0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose
Reported as:
Mean · ng/mL
PK of TAF and TFV: Cmax at Weeks 16, 22, or 28
ng/mLGroup 3: Oral LEN + F/TAF
TAF308.7 ± 74.7
TFV31.2 ± 51.7
SecondaryPK of TAF and TFV: Tmax at Weeks 16, 22, or 28

Tmax is defined as the time (observed time point) of Cmax. A PK substudy was conducted in at least 15 participants in the treatment group receiving oral LEN (Treatment Group 3). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. For each participant, PK samples were taken at only one of the three possible visits: Weeks 16, 22, or 28. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.

Time frame:
0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose
Reported as:
Median · hours
PK of TAF and TFV: Tmax at Weeks 16, 22, or 28
hoursGroup 3: Oral LEN + F/TAF
TAF0.53 (0.50 to 1.04)
TFV1.00 (1.00 to 2.00)
SecondaryPK of TFV: Clast at Weeks 16, 22, or 28

Clast is defined as the last observable concentration of drug. A PK substudy was conducted in at least 15 participants in the treatment group receiving oral LEN (Treatment Group 3). Key PK parameters of TFV was summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. For each participant, PK samples were taken at only one of the three possible visits: Weeks 16, 22, or 28. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.

Time frame:
0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose
Reported as:
Mean · ng/mL
PK of TFV: Clast at Weeks 16, 22, or 28
ng/mLGroup 3: Oral LEN + F/TAF
PK of TFV: Clast at Weeks 16, 22, or 2822.2 ± 62.6
SecondaryPK of TAF: AUClast at Week 38

AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TAF was summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 at Week 38.

Time frame:
0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose
Reported as:
Mean · h*ng/mL
PK of TAF: AUClast at Week 38
h*ng/mLGroup 1: SC LEN+(F/TAF→ TAF)
PK of TAF: AUClast at Week 38211.5 ± 74.1
SecondaryPK of TAF: Cmax at Week 38

Cmax is defined as the maximum observed concentration of drug. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TAF was summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 at Week 38.

Time frame:
0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose
Reported as:
Mean · ng/mL
PK of TAF: Cmax at Week 38
ng/mLGroup 1: SC LEN+(F/TAF→ TAF)
PK of TAF: Cmax at Week 38279.0 ± 67.8
SecondaryPK of TAF: Tmax at Week 38

Tmax is defined as the time (observed time point) of Cmax. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TAF was summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 at Week 38.

Time frame:
0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose
Reported as:
Median · hours
PK of TAF: Tmax at Week 38
hoursGroup 1: SC LEN+(F/TAF→ TAF)
PK of TAF: Tmax at Week 380.50 (0.50 to 0.50)
SecondaryPK of Tenofovir Diphosphate (TFV-DP): AUClast at Weeks 4, 10, 16, or 22

AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. A peripheral blood mononuclear cell (PBMC) substudy was conducted in a total of approximately 15 participants in Treatment Groups 1 and 2. For each participant, PK samples were taken at only one of the four possible visits: Weeks 4, 10, 16, or 22. A 12-hour postdose sample was collected, if possible. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.

Time frame:
0 hours (Predose) and at 1, 2, and 6 hours postdose
Reported as:
Mean · h*μM
PK of Tenofovir Diphosphate (TFV-DP): AUClast at Weeks 4, 10, 16, or 22
h*μMGroup 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)
PK of Tenofovir Diphosphate (TFV-DP): AUClast at Weeks 4, 10, 16, or 2216.2 ± 68.321.6 ± 71.9
SecondaryPK of TFV-DP: Cmax at Weeks 4, 10, 16, or 22

Cmax is defined as the maximum observed concentration of drug. A PBMC substudy was conducted in a total of approximately 15 participants in Treatment Groups 1 and 2. For each participant, PK samples were taken at only one of the four possible visits: Weeks 4, 10, 16, or 22. A 12-hour postdose sample was collected, if possible. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.

Time frame:
0 hours (Predose) and at 1, 2, and 6 hours postdose
Reported as:
Mean · micrometer (μM)
PK of TFV-DP: Cmax at Weeks 4, 10, 16, or 22
micrometer (μM)Group 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)
PK of TFV-DP: Cmax at Weeks 4, 10, 16, or 223.3 ± 37.54.3 ± 71.8
SecondaryPK of TFV-DP: Tmax at Weeks 4, 10, 16, or 22

Tmax is defined as the time (observed time point) of Cmax. A PBMC substudy was conducted in a total of approximately 15 participants in Treatment Groups 1 and 2. For each participant, PK samples were taken at only one of the four possible visits: Weeks 4, 10, 16, or 22. A 12-hour postdose sample was collected, if possible. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.

Time frame:
0 hours (Predose) and at 1, 2, and 6 hours postdose
Reported as:
Median · hours
PK of TFV-DP: Tmax at Weeks 4, 10, 16, or 22
hoursGroup 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)
PK of TFV-DP: Tmax at Weeks 4, 10, 16, or 222.00 (1.00 to 6.00)6.00 (1.00 to 6.00)
SecondaryPK of Bictegravir (BIC): AUClast at Week 38

AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). At Week 38, samples were analyzed for BIC only in Treatment Group 2.

Time frame:
0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose
Reported as:
Mean · h*ng/mL
PK of Bictegravir (BIC): AUClast at Week 38
h*ng/mLGroup 2: SC LEN + (F/TAF → BIC)
PK of Bictegravir (BIC): AUClast at Week 3872865.9 ± 31.0
SecondaryPK of BIC: Cmax at Week 38

Cmax is defined as the maximum observed concentration of drug. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). At Week 38, samples were analyzed for BIC only in Treatment Group 2.

Time frame:
0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose
Reported as:
Mean · ng/mL
PK of BIC: Cmax at Week 38
ng/mLGroup 2: SC LEN + (F/TAF → BIC)
PK of BIC: Cmax at Week 3810180.0 ± 42.8
SecondaryPK of BIC: Tmax at Week 38

Tmax is defined as the time (observed time point) of Cmax. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). At Week 38, samples were analyzed for BIC only in Treatment Group 2.

Time frame:
0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose
Reported as:
Median · hours
PK of BIC: Tmax at Week 38
hoursGroup 2: SC LEN + (F/TAF → BIC)
PK of BIC: Tmax at Week 382.00 (1.00 to 3.00)
SecondaryPK of BIC: Clast at Week 38

Clast is defined as the last observable concentration of drug. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). At Week 38, samples were analyzed for BIC only in Treatment Group 2.

Time frame:
0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose
Reported as:
Mean · ng/mL
PK of BIC: Clast at Week 38
ng/mLGroup 2: SC LEN + (F/TAF → BIC)
PK of BIC: Clast at Week 388474.5 ± 33.3

Adverse events

Collected over Adverse Events: Up to 174.9 weeks ; All-Cause Mortality: Up to 189 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: SC LEN+(F/TAF→ TAF)1/52 (1.9%)4/52 (7.7%)47/52 (90.4%)
Group 2: SC LEN + (F/TAF → BIC)0/53 (0%)4/53 (7.5%)46/53 (86.8%)
Group 3: Oral LEN + F/TAF1/52 (1.9%)7/52 (13.5%)42/52 (80.8%)
Group 4: B/F/TAF0/26 (0%)0/25 (0%)19/25 (76%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventGroup 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)Group 3: Oral LEN + F/TAFGroup 4: B/F/TAF
Lymphadenopathy mediastinalBlood and lymphatic system disorders1/520/530/520/25
VomitingGastrointestinal disorders1/520/530/520/25
DeathGeneral disorders0/520/531/520/25
CholecystitisHepatobiliary disorders1/520/530/520/25
AppendicitisInfections and infestations0/520/531/520/25
Pneumocystis jirovecii pneumoniaInfections and infestations0/520/531/520/25
PneumoniaInfections and infestations1/520/530/520/25
Staphylococcal infectionInfections and infestations1/520/530/520/25
PoisoningInjury, poisoning and procedural complications0/520/531/520/25
Diabetic ketoacidosisMetabolism and nutrition disorders1/520/530/520/25
Most frequent other events
Showing 10 of 63
Most frequent other events
EventGroup 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)Group 3: Oral LEN + F/TAFGroup 4: B/F/TAF
Injection site erythemaGeneral disorders25/5218/530/520/25
Injection site swellingGeneral disorders17/5218/530/520/25
Injection site painGeneral disorders15/5214/530/520/25
InfluenzaInfections and infestations13/525/5311/520/25
Injection site noduleGeneral disorders11/5213/530/520/25
Injection site inflammationGeneral disorders12/524/530/520/25
Injection site indurationGeneral disorders11/5211/530/520/25
Covid-19Infections and infestations10/529/5311/524/25
NauseaGastrointestinal disorders10/525/537/521/25
HeadacheNervous system disorders10/528/539/523/25

Baseline characteristics

Safety Analysis Set included all participants who were randomized and received at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)Group 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)Group 3: Oral LEN + F/TAFGroup 4: B/F/TAFTotal
<=18 years00000
Between 18 and 65 years52535125181
>=65 years00101
Age, Continuous
Age, Continuous(years)Group 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)Group 3: Oral LEN + F/TAFGroup 4: B/F/TAFTotal
Mean33 ± 9.530 ± 8.832 ± 12.333 ± 11.132 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)Group 3: Oral LEN + F/TAFGroup 4: B/F/TAFTotal
Female516012
Male47524625170
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)Group 3: Oral LEN + F/TAFGroup 4: B/F/TAFTotal
Race — American Indian or Alaska Native10001
Race — Asian10102
Race — Black2424311695
Race — Native Hawaiian or Pacific Islander11002
Race — White232819878
Race — Other20114
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)Group 3: Oral LEN + F/TAFGroup 4: B/F/TAFTotal
Ethnicity — Hispanic or Latino2521241282
Ethnicity — Not Hispanic or Latino27322813100
Region of Enrollment
Region of Enrollment(Participants)Group 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)Group 3: Oral LEN + F/TAFGroup 4: B/F/TAFTotal
Puerto Rico11518
United States37423721137
Dominican Republic141010337
Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA)
Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA)(log10 copies/mL)Group 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)Group 3: Oral LEN + F/TAFGroup 4: B/F/TAFTotal
Mean4.18 ± 0.6724.35 ± 0.6704.33 ± 0.7224.35 ± 0.7804.30 ± 0.700
HIV-1 RNA Categories
HIV-1 RNA Categories(Participants)Group 1: SC LEN+(F/TAF→ TAF)Group 2: SC LEN + (F/TAF → BIC)Group 3: Oral LEN + F/TAFGroup 4: B/F/TAFTotal
<= 100,000 copies/mL47444321155
> 100,000 copies/mL599427

3 further baseline measures are reported on the registry.

08

Study locations

53 sites
  • Valleywise Community Health Center - McDowell
    Phoenix, Arizona 85004, United States
  • Pueblo Family Physicians
    Phoenix, Arizona 85015, United States
  • Ruane Clinical Research Group Inc
    Los Angeles, California 90036, United States
  • Mills Clinical Research at Men's Health Foundation
    Los Angeles, California 90069, United States
  • Eisenhower Health Center at Rimrock
    Palm Springs, California 92264, United States
  • University of Colorado, Denver, University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • Denver Public Health
    Denver, Colorado 80204, United States
  • Yale University; School of Medicine
    New Haven, Connecticut 06510, United States
  • Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • Whitman-Walker Institute, Inc.
    Washington, District of Columbia 20009, United States
  • Washington Health Institute
    Washington, District of Columbia 20017, United States
  • Midland Florida Clinical Research Center, LLC
    DeLand, Florida 32720, United States
  • Midway Immunology and Research Center
    Fort Pierce, Florida 34982, United States
  • Floridian Clinical Research
    Hialeah, Florida 33016, United States
  • AIDS Healthcare Foundation - South Beach
    Miami Beach, Florida 33140, United States
  • AHF-The Kinder Medical Group
    Miami, Florida 33133, United States
  • Orlando Immunology Center
    Orlando, Florida 32803-1851, United States
  • St. Joseph's Hospital Comprehensive Research Institute
    Tampa, Florida 33614, United States
  • Triple O Research Institute, P.A.
    West Palm Beach, Florida 33401, United States
  • Atlanta ID Group, PC
    Atlanta, Georgia 30309, United States
  • August University Medical Center
    Augusta, Georgia 30912, United States
  • Infectious Disease Specialists of Atlanta
    Decatur, Georgia 30033, United States
  • Mercer University, Department of Internal Medicine
    Macon, Georgia 31201, United States
  • Chatham County Health Department
    Savannah, Georgia 31401, United States
  • Howard Brown Health Center
    Chicago, Illinois 60613, United States
  • Northstar Healthcare
    Chicago, Illinois 60657, United States
  • Indiana University Infectious Diseases Research
    Indianapolis, Indiana 46077, United States
  • Be Well Medical Center
    Berkley, Michigan 48072, United States
  • St. John Newland Medical Associates
    Southfield, Michigan 48075, United States
  • KC CARE Health Center
    Kansas City, Missouri 64111, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • AHF-Midtown
    New York, New York 10001, United States
  • East Carolina University, The Brody School of Medicine
    Greenville, North Carolina 27858, United States
  • Rosedale Infectious Diseases
    Huntersville, North Carolina 28078, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • Case Clinical Research Site/University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • The Ohio State University Medical Center
    Columbus, Ohio 43210, United States
  • Allegheny Health Network
    Pittsburgh, Pennsylvania 15212, United States
  • St. Jude Children's Research Hospital
    Memphis, Tennessee 38105, United States
  • Central Texas Clinical Research
    Austin, Texas 78705, United States
  • St Hope Foundation
    Bellaire, Texas 77401, United States
  • Prism Health North Texas
    Dallas, Texas 75208, United States
  • North Texas Infectious Diseases Consultants, P.A.
    Dallas, Texas 75246, United States
  • Texas Centers for Infectious Disease Associates
    Fort Worth, Texas 76104, United States
  • The Crofoot Research Center, Inc.
    Houston, Texas 77098, United States
  • DCOL Center for Clinical Research
    Longview, Texas 75605, United States
  • Clinical Alliance for Research & Education - Infectious Diseases, LLC (CARE-ID)
    Annandale, Virginia 22003, United States
  • Peter Shalit, M.D.
    Seattle, Washington 98104, United States
  • MultiCare Rockwood HIV Critical Care Clinic
    Spokane, Washington 99204, United States
  • Instituto Dominicano de Estudios Virológicos (IDEV)
    Santo Domingo, 10103, Dominican Republic
  • Clinical Research Puerto Rico
    San Juan, 00909-1711, Puerto Rico
  • HOPE Clinical Research
    San Juan, 00909, Puerto Rico
  • Proyecto ACTU, School of Medicine, University of Puerto Rico
    San Juan, 00935, Puerto Rico
09

References and documents

Publications

  • Gupta SK, Berhe M, Crofoot G, Benson P, Ramgopal M, Sims J, McDonald C, Ruane P, Sanchez WE, Scribner A, Liu SY, VanderVeen LA, Dvory-Sobol H, Rhee MS, Baeten JM, Koenig E. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. Lancet HIV. 2023 Jan;10(1):e15-e23. doi: 10.1016/S2352-3018(22)00291-0. PubMed 36566079 ↗
  • VanderVeen, L. A., et al. Resistance Analysis of Long-Acting Lenacapavir in People With HIV Who are Treatment-Naïve After 80 Weeks of Treatment [Poster14]. European Meeting on HIV & Hepatitis 2023, Rome, Italy.
  • Jogiraju V, Shelton M, Dheri P, Ling J, Wang H, Dvory-Sobol H, et al. Pharmacokinetics of Lenacapavir Alone and When Coadministered With Other Antiretrovirals in People With HIV [Poster PII-056]. American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting; 2023 22-24 March; Atlanta, GA.
  • Hagins D, Koenig E, Safran R, Santiago L, Wohlfeiler M, Hsiao C, et al. Long-Acting Lenacapavir in a Combination Regimen for Treatment Naïve PWH: Week 80 [Poster 522]. Conference on Retroviruses and Opportunistic Infections (CROI); 2023 19-22 February; Seattle, WA.
  • VanderVeen LA, Margot N, Naik V, Dvory-Sobol H, Rhee MS, Callebaut C. Resistance Analysis of Long-Acting Lenacapavir in Treatment-Naïve People With HIV at 54 Weeks [Poster EPB239]. AIDS 2022; 2022 29 July-2 August; Montreal, Quebec, Canada.
  • Gupta SK, Sims J, Brinson C, Cruickshank FA, Oguchi G, Morales J, et al. Lenacapavir as part of a Combination Regimen in Treatment-Naïve People with HIV: Week 54 Results [Presentation]. Virtual Conference on Retroviruses and Opportunistic Infections (CROI) 2022; 2022 12-16 February.
  • VanderVeen, L, Margot N, Naik V, et al. Interim Resistance Analysis of Long-Acting Lenacapavir in Treatment-Naïve People with HIV at 28 Weeks (CALIBRATE) [Abstract Oral 73]. Presented at: ID Week; 2021 September 29 - October 03.
  • Gupta SK, Berhe M, Crofoot G, et al. Long-Acting Subcutaneous Lenacapavir Dosed Every 6 Months as part of a Combination Regimen in Treatment-Naïve People with HIV: Interim 16-week Results of a Randomized, Open-label, Phase 2 Induction-Maintenance Study (CALIBRATE) [Abstract OALB0302]. Presented at: International AIDS Society (IAS) Conference; 2021 July 18-21.
  • Harris P, Henderson R, Hayward P. Highlights from the 11th IAS Conference on Science. Lancet HIV. 2021 Aug;8(8):e459. doi: 10.1016/S2352-3018(21)00161-2. No abstract available. PubMed 34358495 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gileadclinicaltrials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Oct 2021, 22 months.

Results were first posted in Dec 2022, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2019
First posted
Oct 29, 2019
StartActual
Nov 22, 2019
Primary completionActual
Oct 5, 2021
CompletionActual
Sep 19, 2023
Results first posted
Dec 19, 2022
Last update
Oct 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04143594
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Oct 29, 2019
Start date
Nov 22, 2019
Primary completion
Oct 5, 2021
Completion
Sep 19, 2023
Results posted
Dec 19, 2022
Last update
Oct 2, 2024

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenacapavir · Bictegravir · Emtricitabine · Tenofovir alafenamide

Start the discussion